Abstract library

237 results for "18FDG".
#562 Expression of Chromosome 18 Related Tumor Suppressor Proteins in Ileal Neuroendocrine Tumors
Introduction: The genetic alterations in ileal neuroendocrine tumors (iNETs) are poorly
characterized. The most frequent chromosomal aberration is the loss of one
chromosome 18 in iNETs, however, the relevance of this alteration is unclear.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr. Tobias Henopp
#730 Loss of Chromosome 18 in Neuroendocrine Tumors of the Midgut
Introduction: The genetic alterations in neuroendocrine tumors (NET) of the midgut, in particular of the appendix (aNET), are poorly characterized. The most frequent chromosomal aberration in ileal NET (iNET) is the loss of one chromosome 18. The relevance of this alteration is unclear.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: MD Tobias Henopp
Keywords: chr18
#262 Changes on Chromosome 18 are Involved in Sporadic and Familial Ileal Carcinoid Tumor Development
Introduction: Small intestine neuroendocrine tumors (ileal carcinoid) is generally considered a sporadic disease. We have identified nine families with an ileal carcinoid tumor diagnosed in two or more individuals.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Professor Eva Tiensuu Janson
#700 Comparative Expression Analysis of Chromosome 18 Related miRNAs in Ileal NET with and without Chr18 Loss
Introduction: MicroRNAs (miRs) play important roles in many kinds of biological processes. Because the (partial) loss of one chromosome 18 (Chr18) is a frequent event in ileal NETs (iNETs), we assessed the potential deregulation of miR-expression in these patients.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Maike Hoffmeister
Keywords: NET, mir-expression
#88 EpCam expression and detection of circulating tumor cells in neuroendocrine tumors
Introduction: Using the CellSearchTM system, circulating tumor cells (CTCs) can be reproducibly enumerated according to expression of EpCAM and cytokeratins 8, 18 or 19 and the absence of the haemopoietic marker CD45. The number of CTCs detected in 7.5 mls blood has been shown to correlate with prognosis in breast, colon and prostate cancer and can predict response to therapy. Neuroendocrine tumors (NETs) have not previously been reported to express EpCAM and have not been systematically assessed for presence of CTCs. We have therefore explored the expression of EpCAM in NETs and the detection of NET cells in the circulation.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#549 Long-Acting Somatostatin Analogues are Highly Effective in Patients with Early Stage MEN-1-Related Well-Differentiated Neuroendocrine Tumors
Introduction: Somatostatin analogues (SSA) represent one of the main therapeutic options in patients affected with functioning well-differentiated neuroendocrine tumors (NET). There are no studies specifically focusing on NET associated to Multiple Endocrine Neoplasia type 1 (MEN-1).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Antongiulio Faggiano
#886 Expression Patterns of Cellular Retinoic Acid Binding Protein-I in Neuroendocrine Tumors of the Lung: A Pilot Immunohistochemical Study
Introduction: Cellular retinoic acid binding protein-I (CRABP-I), a member of the lipid-binding proteins family, plays an important role in retinoic acid-mediated cell proliferation and is essential for the development of various malignant neoplasms. The actual role of CRABP-I in tumor progression remains unknown.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Vera Delektorskaya
#1708 STREET - Somatostatin Treatment Experience Trial
Introduction: Somatostatin analogs (SSA) delay progress and decrease symptoms in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). It is not known whether patients’ experiences of injection treatment differ between different SSAs.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Ass. prof. Martin Almquist
#1855 Total 68Ga-DOTATATE-Avid Tumor Volume (TV) Predicts Progression-Free Survival (PFS) and Disease-Specific Mortality (DSM) in Patients with Neuroendocrine Tumors (NETs)
Introduction: Patients with NETs have divergent survival, even when having the same site of primary tumor, tumor stage and grade. 68Ga-DOTATATE PET/CT has emerged as a sensitive imaging modality for detecting NETs.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Amit Tirosh
#2169 Patient and Clinician Perspectives on Symptom Priorities Across the Spectrum of Neuroendocrine Tumors (NETs)
Introduction: NETs are associated with a range of symptoms, and symptom reduction is a common treatment target. Identifying priority symptoms across NETs can help inform clinical trial endpoints.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Research Prof Kimberly Webster